impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Review

 

A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis

1, 2, 3, 4, 5, 6

 

  1. School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea.
  2. School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea.
  3. Department of Information Statistics, Andong National University, Gyeongsangbuk-do, South Korea.
  4. College of Pharmacy, Sahmyook University, Seoul, South Korea.
  5. School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea.
  6. School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea. ekyung@skku.edu

CER9883
2017 Vol.35, N°4
PI 0689, PF 0699
Review

Free to view
(click on article PDF icon to read the article)

PMID: 28079510 [PubMed]

Received: 31/08/2016
Accepted : 21/11/2016
In Press: 05/01/2017
Published: 13/07/2017

Abstract

OBJECTIVES:
The purpose of this study was to compare the discontinuation rates of tofacitinib and biologics (tumour necrosis factor inhibitors (TNFi), abatacept, rituximab, and tocilizumab) in rheumatoid arthritis (RA) patients considering inadequate responses (IRs) to previous treatment(s).
METHODS:
Randomised controlled trials of tofacitinib and biologics – reporting at least one total discontinuation, discontinuation due to lack of efficacy (LOE), and discontinuation due to adverse events (AEs) – were identified through systematic review. The analyses were conducted for patients with IRs to conventional synthetic disease-modifying anti-rheumatic drugs (cDMARDs) and for patients with biologics-IR, separately. Bayesian network meta-analysis was used to estimate rate ratio (RR) of a biologic relative to tofacitinib with 95% credible interval (CrI), and probability of RR being <1 (P[RR<1]).
RESULTS:
The analyses of 34 studies showed no significant differences in discontinuation rates between tofacitinib and biologics in the cDMARDs-IR group. In the biologics-IR group, however, TNFi (RR 0.17, 95% CrI 0.01–3.61, P[RR<1] 92.0%) and rituximab (RR 0.20, 95% CrI 0.01–2.91, P[RR<1] 92.3%) showed significantly lower total discontinuation rates than tofacitinib did. Despite the difference, discontinuation cases owing to LOE and AEs revealed that tofacitinib was comparable to the biologics.
CONCLUSIONS:
The comparability of discontinuation rate between tofacitinib and biologics was different based on previous treatments and discontinuation reasons: LOE, AEs, and total (due to other reasons). Therefore, those factors need to be considered to decide the optimal treatment strategy.

Rheumatology Article